Clinical Trials Browser

Phase 1/2 × Recurrence × glofitamab × Clear all

NCT06634589 2026-03-18

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT05896163 2025-10-20

MAPtivate-6

Phase 1/2 Active not recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse